Now showing items 1-10 of 14
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
(Elsevier/Science Direct, 2018-11-02)
BACKGROUND: Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with ...
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
This is the accepted manuscript of an article published online: 1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908